Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer To Streamline Structure To Minimize Bureaucracy And Fuel “Entrepreneurial” Spirit

This article was originally published in The Pink Sheet Daily

Executive Summary

Organization has 12 to 13 layers, vice chairman says, while some best-in-class companies have five to seven.

You may also be interested in...



Pfizer Restructuring Expands Shedlarz' Responsibilities As Katen Departs

New CEO Jeffrey Kindler also establishes a seven member "Executive Leadership Team."

Sage's Regulatory Strategy For Zuranolone Remains Uncertain

The company said it will update investors on the path forward for zuranolone in major depressive disorder after finalizing discussions with the US FDA. It would not confirm if a meeting had taken place yet.

Drug Shortages Loom If Coronavirus Persists In China, Generics Execs Say

Drug shortages will become a bigger issue in a few months if ingredient supply disruptions in China persist, Bernstein analyst Gal concluded from discussions with four generic executives. 

Topics

UsernamePublicRestriction

Register

PS064934

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel